“…The volumes of PCDD/F and DL-PCB eluates were reduced to 0.5 mL, transferred to a conical 1.2 mL vial, and carefully reduced further to 2–3 µL, followed by exchange of the solvent for 7 µL of DMSO in the case of the PCB-fraction, and for 14 µL of DMSO in the case of the dioxin/furan-fraction, following a well-established procedure, which keeps vial-to-vial variability, expressed as relative standard deviation (RSD), below 5%. The smaller volume for the final extract containing DL-PCBs was chosen due to a reduced relative potency (REP) or response of the cell bioassay to PCB 126, the most abundant DL-PCB, which is approximately 40% compared to the response of the assay to the most potent compound, 2,3,7,8-TCDD [ 21 , 35 – 38 ]. The small final extract volumes provide concentration factors of, roughly, 700 for DL-PCBs and 350 for PCDD/Fs, the magnitude of which may pose a challenge to the control of unwanted and potentially interfering co-extractives or co-eluents altering the cell response.…”